Relationship between β-Thalassemia minor and Helicobacter pylori infection by Sharbatdaran, Majid et al.
Caspian J Intern Med 2018; 9(1):60-64  
DOI: 10.22088/cjim.9.1.60 
    Original Article 
 
 
 
 
 
Majid Sharbatdaran (MD) 1, 2 
Amin Holaku (MD) 2 
Mehrdad Kashifard (MD) 1 
Ali Bijani (MD) 3 
Alireza Firozjahi (MD) 1, 2 
Akram Hosseini (MD) 1, 2 
Sepideh Siadati (MD) 1, 2* 
 
 
 
1. Cancer Research Center, Health 
Research Institute, Faculty of 
Medicine, Babol University of 
Medical Sciences, Babol, Iran 
2. Department of Pathology, 
Faculty of Medicine, Babol 
University of Medical Sciences, 
Babol, Iran 
3. Social determinates Faculty of 
Medicine, Babol University of 
Medical Sciences, Babol, Iran 
 
 
 
* Correspondence: 
Sepideh Siadati, Cancer Research 
Center, Health Research Institute, 
Babol University of Medical 
Sciences, Babol, Iran 
 
 
 
E-mail: 
siadati_sepideh@yahoo.com 
Tel: 0098 1132256285 
Fax: 0098 132256285 
 
 
 
 
 
 
 
 
 
 
 
 
 
Received: 22 April 2015  
Revised: 18 Oct 2017 
Accepted: 12 Aug 2017 
 
Fecal calprotectin Level in patients with IBD and 
noninflammatory disease of colon: a study in Babol, 
Northern, Iran 
 
Abstract 
Background: Inflammatory bowel disease (IBD) is a chronic disease with a relapsing 
course of inflammation in the digestive system. Endoscopy and histopathology are the 
golden standard methods for detection and assessment of IBD. A distinct increase of fecal 
calprotectin level can be a useful marker for the diagnosis of IBD. The aim of this study 
was to evaluate the fecal calprotectin level in patients with IBD and without inflammatory 
diseases of the colon. 
Methods: Calprotectin levels of patients referred to the Ayatollah Rouhani Hospital of 
Babol, northern Iran with clinical symptoms of colon disease were evaluated. After a 
week, colonoscopy and biopsy were performed on all patients and they were divided into 
two groups. The first group included patients with confirmed IBD and the second group 
included patients with diseases other than IBD, patients with IBS and healthy persons. 
Then the measured fecal calprotectin level was compared between the two groups before 
colonoscopy. 
Results: We observed correlation between calprotection in these two groups (p<0.0001). 
38 (86.8%) patients in the case group and 5 (13.2%) patients in the control group had 
positive fecal calprotectin test and 12 (23.1%) patients in the case group and 40 (76.9%) 
patients in the control group had negative results. Basad on ROC curve, the cutoff point of 
calprotectin was 127.65 with 73% sensitivity and 89% specificity. The area under the 
curve was 0.83 with 95% confidence interval, 0.74-0.91 (p<0.0001). 
Conclusions: The results pointed to this fact that fecal calprotectin can be a noninvasive 
marker in differentiating IBD from IBS. 
Keywords: Fecal calprotectin level, Inflammatory bowel disease, Irritable bowel syndrome. 
 
Citation: 
Sharbatdaran M, Holaku A, Kashifard M, et al. Fecal calprotectin Level in patients with IBD and 
noninflammatory disease of colon: a study in Babol, Northern, Iran. Caspian J Intern Med 2018; 
9(1):60-64. 
 
Ulcerative colitis (UC) and Crohn's disease are chronic disorders of the 
gastrointestinal tract, known as inflammatory bowel diseases (IBD). The symptoms of IBD 
vary between periods of improvement and flare (1). IBD is more common in developed 
countries and reaches approximately 1-2 case(s) per 1000 population and its increasing 
prevalence in both adults and children (2). Due to the common symptoms of IBD with 
irritable bowel syndrome (IBS) and functional gastrointestinal disorders, the high cost and 
invasiveness of diagnostic procedures such as endoscopy, barium enema, CT scan and 
biopsy, low sensitivity and specificity of serologic (CRP) and hematological (ESR) 
parameters  related to the symptoms and signs of IBD, physicians use a combination of 
clinical signs and symptoms, laboratory indices, radiology, colonoscopy and 
histopathology to diagnose the disease, assess its severity and predict the outcome (2-5). 
Among all these methods, endoscopy and histopathology are the golden standard methods 
in diagnosing IBD (5, 6).    
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Using traditional tests is still questionable assuming 
whether patients with IBD are in recovery or not. Findings of 
Simren et al. showed that 57% of patients with Crohn's 
disease and 33% of patients with UC had symptoms like 
IBS, despite being in a long term recovery period (7). 
Recently, Keohane et al. confirmed the results of Simren et 
al. and reported the prevalence of IBS like the symptoms 
among patients with Crohn's disease and UC was 59.7 and 
38.6, respectively (7, 8). Calprotectin is a calcium binding 
protein, which forms approximately 60% protein content of 
cytosolic neutrophils and mononuclear cells (9).  
Calprotectin is a protein composed of two heavy chains 
(L1H) and a light chain (L1L); these two chains are linked 
together by noncovalent bonds (10-12). Calprotectin is one 
of the most important regulatory proteins in the 
inflammatory response (13-15). Studies on children and 
adults have shown that there was a correlation between fecal 
calprotectin and the severity of mucosal inflammation (16, 
17). Since it is not possible to differentiate IBD from IBS in 
many cases, using a marker is justified to differentiate the 
two diseases. Although the extensive serological research 
studies have been done to differentiate IBD from IBS in 
recent years, there has been little success (18).  
Significant increase of fecal calprotectin levels is 
considered as a useful marker for the diagnosis of intestinal 
inflammation among the laboratory parameters due to its low 
cost and easy to measure (approximately 5 g), excellent 
stability at room temperature for a week and the ability to be 
examined using ELISA immunoassay kits (5, 6). Roseth et 
al. Schoepfer et al. and Keohane et al. have approved some 
hopeful results when they measured the fecal calprotectin 
(zinc binding protein) (8, 9, 18).  
The aim of this study was to evaluate the level of fecal 
calprotectin in patients with IBD and patients without 
inflammatory diseases of the colon. 
 
 
Methods 
The present case-control study was conducted on patients 
referred to a gastroenterologist in Ayatollah Rouhani 
Hospital of Babol, northern Iran with clinical symptoms of 
colon diseases during 2013-2014. Participants were older 
than 18 years, which include both genders. All patients had 
an indication for colonoscopy, which was diagnosed by 
gastroenterologist. The exclusion criteria included suffering 
from any chronic disease and illness that caused fever in 
patients. Sampling method was relatively easy and the 
information of the patients such as age, gender, education 
and occupation was written in the form. Finally, 90 patients 
were entered into this study. First, the calprotectin levels of 
all patients were measured and recorded. Calprotectin test 
was performed using ELISA method by the Buhlmann 
Laboratories Kit made in Switzerland. Calprotectin less than 
50μg is considered negative and more than 200μg is 
considered positive. Patients with calprotectin level of 50-
200μg were excluded from the study, however follow-up 
was done. 
The colonoscopy was performed on all patients one week 
after their calprotectin was measured. During colonoscopy, 
three biopsies were taken from the most severe local 
inflammation and were sent to pathology department. Then 
40 patients diognosed with IBD were divided into two 
groups (45 per group) according to the results of the 
colonoscopy and biopsy. The first group included patients 
with confirmed IBD and the second or control group 
included patients with inflammatory bowel diseases other 
than IBD, patients with IBS and healthy persons. After that, 
the measured fecal calprotectin levels before colonoscopy 
were compared in two groups. 
Data were analyzed with SPSS Version 22 software and 
ROC curve. Area under the ROC curve was considered as 
diagnostic value of calprotectin and with the 95% confidence 
interval. Also, using the ROC curve, sensitivity and 
specificity of cutoff point was calculated. Therefore reduced 
false positive and false negative, Mann-Whitney, chi-square 
and t-test were used for quantitative and qualitative 
variables. A p-value<0.05 was considered significant. 
 
 
Results 
The mean age of patients was 34.69±10.42 years. Totally, 
39 (43.3%) males and 51 (56.7%) females participated in the 
present study (table 1). There was significant result between 
calprotectin and both groups (p<0.0001), thus 33 (73.3%) 
patients in the case group and 5 (11.1%) patients in the 
control group had positive fecal calprotectin test while 12 
(26.7%) patients in the case group and 40 (88.9%) patients in 
the control group had negative results. The diagnostic value 
of calprotectin in comparison with biopsy was evaluated. 
According to the ROC curve, cutoff point of calprotectin was 
127.65 with 73% specificity and 89% sensitivity, 
respectively (table 2). 
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Table 1. Comparison of mean of age, fecal calprotectin 
and sex distribution between IBD patients and control 
subjects 
Pvalue Case Control 
Group 
Variables 
0.779 34.38±11.30 35±9.59 Mean age (year) 
0.000 
 
652.8±799.7 
315.9 (48.3-843.5) 
 
98.30±256.1 
42 (32-47.6) 
Calprotectin 
Meam±SD 
Medican (IQR) 
0.395 
 
22 (48.9) 
23 (51.1) 
 
17 (37.8) 
28 (62.2) 
Gender 
Men (%) 
Women (%) 
 
Table 2. Diagnostic precision of calprotectin in IBD 
Diagnostic precision Value 95% CI 
Sensitivity 73% (60%-86%) 
Specificity  89% (80%-98%) 
Positive predictive value 87% (76%-98%) 
Negative predictive value 77% (65%-88%) 
Likelihood ratio+ 6.60 (2.84-15.36) 
Likelihood ratio- 0.30 (0.18-0.49) 
 
Areas under the curve was 0.83 with 95% confidence 
interval, 0.74-0.92 (p<0.0001) (figure1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 ROC curve showing the correlation between 
specificity and sensitivity of calprotectin in the diagnosis 
of IBD. 
 
 
Discussion  
Based on the results, the cutoff point of calprotectin was 
127.65 with 73% specificity and 89% sensitivity. The 
average of calprotectin in case group was higher than the 
other group. Keohane et al. (8) found a significant 
correlation between the increased calprotectin levels in both 
the IBS and IBD patients; Schoepfer et al. (18) expressed 
that the fecal level of this marker can differentiate IBD from 
IBS with high sensitivity and accuracy, which was consistent 
with the results of the present study. Moein et al. 
demonstrated that FC has better effect in the differentiation 
between the subjects with IBD from those without IBD than 
conventional inflammatory marker (19). 
A study in Ireland stated that the combination of clinical 
symptoms with noninvasive markers such as calprotectin 
was very important (8). Although using the laboratory 
markers with this sensitivity is not necessary, these tools can 
be useful (20). On the other hand, various levels of 
calprotectin have been described in several studies to 
differentiate IBD from IBS. Tibble et al. reported that 30 
mg/g level had 100% sensitivity to differentiate IBD from 
IBS (21).  Also, D' Inca et al. and Sipponen et al. suggested 
130 and 200 microgr/gr levels for activating and improving 
the disease, respectively (22, 23). In a recent study published 
by Sipponen et al. the best value has been considered 94 
micrograms per gram. Thus, calprotectin levels can be 
helpful in differentiating IBD from IBS (24). 
Some studies have suggested that fecal calprotectin level 
is significantly higher in some intestinal disorders (including 
esophageal / gastric carcinoma, Crohn's disease, ulcerative 
colitis and colorectal carcinoma) than other disorders 
(Barrett's esophagus, stomach ulcers, gastritis / duodenitis, 
colorectal polyps and adenoma) (25). In this study, only IBD 
was compared to other inflammatory bowel diseases and 
there was no information on other diseases in the control 
group. Besides, the ROC curve analysis confirmed the fact 
that fecal calprotectin level was significantly higher among 
the IBD patients and other individuals (healthy or suffering 
from IBS) and the increase of calprotectin level is associated 
with the increase of IBD risk. 
The strength of the study presented two views of 
calprotectin. First calprotectin was considered as an 
inflammatory factor, then using the ROC curve, it was 
considered as a diagnostic marker. Limitations of this study 
include lack of evaluating and identifying non-inflammatory 
bowel diseases (in the control group). Moreover, the 
relationship between fecal calprotectin and IBD was 
generally compared, but the Crohn's disease and ulcerative 
colitis were not separately studied. In summary, the results 
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showed that fecal calprotectin could be a noninvasive marker 
to differentiate IBD from IBS. Considering the cutoff point 
of calprotectin with 73% sensitivity and 89% specificity, it 
could be used as a diagnostic method to differentiate the 
inflammatory bowel diseases. 
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